Early trials are exploring retatrutides potential applications in prevention and treatments for younger populations
Haq U, Shurjeel Uddin Qazi, Sajid F, et al

Resources: GLP-1 Agonists Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Safety of Semaglutide Once-Weekly Semaglutide in Adults with Overweight or Obesity Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Medication-Induced Gastroparesis: A Case Report Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASSCVOT design and baseline characteristics Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Tirzepatide prevents neurodegeneration through multiple molecular pathways TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Biology of Incretins: GLP-1 and GIP GIP and GLP1, the two incretin hormones: Similarities and differences GLP-1, GIP and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy

[DOI] [PubMed] [Google Scholar] 106.Butsch W.S., Kushner R.F., Alford S., Smolarz B.G
This risk of muscle loss is why we focus on getting enough protein and incorporating resistance exercise during treatment to help maintain muscle mass while losing weight
Australia GLP-1 Receptor Agonist Market Key Players and Potential Contributions AstraZeneca : With drugs like Bydureon, it contributes by offering established injectable GLP-1 options